Update on rhabdomyosarcoma

Seminars in Pediatric Surgery

Volumn 21, Issue 1, 2012, Pages 68-78

  Dasgupta, Roshni ^a   Rodeberg, David A ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Rhabdomyosarcoma; Tumor biology risk stratification

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; IFOSFAMIDE; VINCRISTINE;

ABDOMINAL WALL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MUSCLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; POSTOPERATIVE PERIOD; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; RHABDOMYOSARCOMA; SECOND LOOK SURGERY; THORAX WALL; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

CHILD; COMBINED MODALITY THERAPY; HUMANS; RHABDOMYOSARCOMA;

EID: 84855909201     PISSN: 10558586     EISSN: 15329453     Source Type: Journal    
DOI: 10.1053/j.sempedsurg.2011.10.007     Document Type: Article

References (117)

1. Huh W.W., Skapek S.X. Childhood rhabdomyosarcoma: New insight on biology and treatment. Curr Oncol Rep 2010, 12:402-410.
2. Leaphart C., Rodeberg D. Pediatric surgical oncology: Management of rhabdomyosarcoma. Surg Oncol 2007, 16:173-185.
3. Miller R.W., Young J.L., Novakovic B. Childhood cancer. Cancer 1995, 75:395-405.
4. Toro J.R., Travis L.B., Wu H.J., et al. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: An analysis of 26,758 cases. Int J Cancer 2006, 119:2922-2930.
5. Merlino G., Helman L.J. Rhabdomyosarcoma-Working out the pathways. Oncogene 1999, 18:5340-5348.
6. Taulli R., Scuoppo C., Bersani F., et al. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res 2006, 66:4742-4749.
7. Tarnowski M., Grymula K., Liu R., et al. Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors and inhibits recruitment of cancer-associated fibroblasts. Mol Cancer Res 2010, 8:1328-1343.
8. Zibat A., Missiaglia E., Rosenberger A., et al. Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma. Oncogene 2010, 29:6323-6330.
9. Xu J., Timares L., Heilpern C., et al. Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis. Cancer Res 2010, 70:6566-6576.
10. Chen Y., Takita J., Mizuguchi M., et al. Mutation and expression analyses of the MET and CDKN2A genes in rhabdomyosarcoma with emphasis on MET overexpression. Genes Chromosomes Cancer 2007, 46:348-358.
11. Scrable H., Cavenee W., Ghavimi F., et al. A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting. Proc Natl Acad Sci U S A 1989, 86:7480-7484.
12. Scrable H.J., Johnson D.K., Rinchik E.M., et al. Rhabdomyosarcoma-associated locus and MYOD1 are syntenic but separate loci on the short arm of human chromosome 11. Proc Natl Acad Sci U S A 1990, 87:2182-2186.
13. Scrable H.J., Witte D.P., Lampkin B.C., et al. Chromosomal localization of the human rhabdomyosarcoma locus by mitotic recombination mapping. Nature 1987, 329:645-647.
14. De Giovanni C., Landuzzi L., Nicoletti G., et al. Molecular and cellular biology of rhabdomyosarcoma. Futures Oncol 2009, 5:1449-1475.
15. Makawita S., Ho M., Durbin A.D., et al. Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors. Pediatr Dev Pathol 2009, 12:127-135.
16. El-Badry O.M., Minniti C., Kohn E.C., et al. Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ 1990, 1:325-331.
17. Huang F., Hurlburt W., Greer A., et al. Differential mechanisms of acquired resistance to insulin-like growth factor-I receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. Cancer Res 2010, 70:7221-7231.
18. Kurmasheva R.T., Dudkin L., Billups C., et al. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 2009, 69:7662-7671.
19. Fu P., Liang G.J., Khot S.S., et al. Cross-talk between MAP kinase pathways is involved in IGF-independent, IGFBP-6-induced Rh30 rhabdomyosarcoma cell migration. J Cell Physiol 2010, 224:636-643.
20. Williamson D., Missiaglia E., de Reyniès A., et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 2010, 28:2151-2158.
21. Missiaglia E., Selfe J., Hamdi M., et al. Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: An approach to identify candidate genes involved in tumor development. Genes Chromosomes Cancer 2009, 48:455-467.
22. Martinelli S., McDowell H.P., Vigne S.D., et al. RAS signaling dysregulation in human embryonal rhabdomyosarcoma. Genes Chromosomes Cancer 2009, 48:975-982.
23. Barr FG D.F., Smith L.M., et al. Genomic and clinical analyses of 2p24 and 12q13-q14 amplification in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. Genes Chromosomes Cancer 2009, 48:661-672.
24. Petricoin E.F., Espina V., Araujo R.P., et al. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res 2007, 67:3431-3440.
25. Houghton P.J., Morton C.L., Kolb E.A., et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 50:799-805.
26. Borycki A.G., Li J., Jin F., et al. Pax3 functions in cell survival and in pax7 regulation. Development 1999, 126:1665-1674.
27. Peng H., Huard J. Muscle-derived stem cells for musculoskeletal tissue regeneration and repair. Transpl Immunol 2004, 12:311-319.
28. Parham D.M., Qualman S.J., Teot L., et al. Correlation between histology and PAX/FKHR fusion status in alveolar rhabdomyosarcoma: A report from the children's Oncology Group. Am J Surg Pathol 2007, 31:895-901.
29. Cao L., Yu Y., Bilke S., et al. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res 2010, 70:6497-6508.
30. Davicioni E., Anderson M.J., Finckenstein F.G., et al. Molecular classification of rhabdomyosarcoma-Genotypic and phenotypic determinants of diagnosis: A report from the children's Oncology Group. Am J Pathol 2009, 174:550-564.
31. Davicioni E., Anderson J.R., Buckley J.D., et al. Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: A report from the children's oncology group. J Clin Oncol 2010, 28:1240-1246.
32. Keller C., Arenkiel B.R., Coffin C.M., et al. Alveolar rhabdomyosarcomas in conditional Pax3: Fkhr mice: Cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev 2004, 18:2614-2626.
33. Missiaglia E., Shepherd C.J., Patel S., et al. MicroRNA-206 expression levels correlate with clinical behaviour of rhabdomyosarcomas. Br J Cancer 2010, 102:1769-1777.
34. Li F.P., Fraumeni J.F. Rhabdomyosarcoma in children: Epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst 1969, 43:1365-1373.
35. Malkin D., Friend S.H. Correction: A Li-Fraumeni syndrome p53 mutation. Science 1993, 259:878.
36. Malkin D., Li F.P., Strong L.C., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990, 250:1233-1238.
37. Varley J.M., McGown G., Thorncroft M., et al. Germ-line mutations of TP53 in Li-Fraumeni families: An extended study of 39 families. Cancer Res 1997, 57:3245-3252.
38. Wu R., López-Correa C., Rutkowski J.L., et al. Germline mutations in NF1 patients with malignancies. Genes Chromosomes Cancer 1999, 26:376-380.
39. Lampe A.K., Seymour G., Thompson P.W., et al. Familial neurofibromatosis microdeletion syndrome complicated by rhabdomyosarcoma. Arch Dis Child 2002, 87:444-445.
40. Ruymann F.B., Maddux H.R., Ragab A., et al. Congenital anomalies associated with rhabdomyosarcoma: An autopsy study of 115 cases. A report from the Intergroup rhabdomyosarcoma Study Committee (representing the children's Cancer Study Group, the Pediatric Oncology Group, the United Kingdom children's Cancer Study Group, and the Pediatric InterGroup Statistical Center). Med Pediatr Oncol 1988, 16:33-39.
41. Toth B., Patil K., Erickson J., et al. Carcinogenesis by benzenediazonium sulfate in mice. In Vivo 1998, 12:379-382.
42. Grufferman S., Schwartz A.G., Ruymann F.B., et al. Parents' use of cocaine and marijuana and increased risk of rhabdomyosarcoma in their children. Cancer Causes Control 1993, 4:217-224.
43. Grufferman S., Wang H.H., DeLong E.R., et al. Environmental factors in the etiology of rhabdomyosarcoma in childhood. J Natl Cancer Inst 1982, 68:107-113.
44. Ognjanovic S., Carozza S.E., Chow E.J., et al. Birth characteristics and the risk of childhood rhabdomyosarcoma based on histological subtype. Br J Cancer 2010, 102:227-231.
45. La T.H., Wolden S.L., Rodeberg D.A., et al. Regional nodal involvement and patterns of spread along in-transit pathways in children with rhabdomyosarcoma of the extremity: A report from the Children's Oncology Group. Int J Radiat Oncol Biol Phys 2010, 15:1151-1157.
46. Yokouchi M., Terahara M., Nagano S., et al. Clinical implications of determination of safe surgical margins by using a combination of CT and 18FDG-positron emission tomography in soft tissue sarcoma. BMC Musculoskelet Disord 2011, 12:166.
47. O'Sullivan F., Wolsztynski E., O'Sullivan J., et al. A statistical modeling approach to the analysis of spatial patterns of FDG-PET uptake in human sarcoma. IEEE Trans Med Imaging 2011, Epub ahead of print.
48. Kumar R., Shandal V., Shamim S.A., et al. Clinical applications of PET and PET/CT in pediatric malignancies. Expert Rev Anticancer Ther 2010, 10:755-768.
49. Mody R.J., Bui C., Hutchinson R.J., et al. FDG PET imaging of childhood sarcomas. Pediatr Blood Cancer 2010, 54:222-227.
50. Tateishi U., Hosono A., Makimoto A., et al. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma. Ann Nucl Med 2009, 23:155-161.
51. McCarville M.B. PET-CT imaging in pediatric oncology. Cancer Imaging 2009, 9:35-43.
52. Klem M.L., Grewal R.K., Wexler L.H., et al. PET for staging in rhabdomyosarcoma: An evaluation of PET as an adjunct to current staging tools. J Pediatr Hematol/Oncol 2007, 29:9-14.
53. Franzius C., Juergens K.U. PET/CT in paediatric oncology: Indications and pitfalls. Pediatr Radiol 2009, 39(Suppl 3):446-449.
54. Kleis M., Daldrup-Link H., Matthay K., et al. Diagnostic value of PET/CT for the staging and restaging of pediatric tumors. Eur J Nucl Med Mol Imaging 2009, 36:23-36.
55. Willman J.H., White K., Coffin C.M. Pediatric core needle biopsy: Strengths and limitations in evaluation of masses. Pediatr Dev Pathol 2001, 4:46-52.
56. Salomão D.R., Sigman J.D., Greenebaum E., et al. Rhabdomyosarcoma presenting as a parotid gland mass in pediatric patients: Fine-needle aspiration biopsy findings. Cancer 1998, 84:245-251.
57. Chowdhury T., Barnacle A., Haque S., et al. Ultrasound-guided core needle biopsy for the diagnosis of rhabdomyosarcoma in childhood. Pediatr Blood Cancer 2009, 53:356-360.
58. McMulkin H.M., Yanchar N.L., Fernandez C.V., et al. Sentinel lymph node mapping and biopsy: A potentially valuable tool in the management of childhood extremity rhabdomyosarcoma. Pediatr Surg Int 2003, 19:453-456.
59. Kayton M.L., Delgado R., Busam K., et al. Experience with 31 sentinel lymph node biopsies for sarcomas and carcinomas in pediatric patients. Cancer 2008, 112:2052-2059.
60. Gow K.W., Rapkin L.B., Olson T.A., et al. Sentinel lymph node biopsy in the pediatric population. J Pediatr Surg 2008, 43:2193-2198.
61. De Corti F., Dall'Igna P., Bisogno G., et al. Sentinel node biopsy in pediatric soft tissue sarcomas of extremities. Pediatr Blood Cancer 2009, 52:51-54.
62. Hays D.M., Lawrence W., Wharam M., et al. Primary reexcision for patients with "microscopic residual" tumor following initial excision of sarcomas of trunk and extremity sites. J Pediatr Surg 1989, 24:5-10.
63. Meza J.L., Anderson J., Pappo A.S., et al. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: The children's Oncology Group. J Clin Oncol 2006, 24:3844-3851. Children's Oncology Group.
64. Rodeberg D.A., Anderson J.R., Arndt C.A., et al. Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma of the bladder/prostate: Combined results from the children's Oncology Group, German Cooperative Soft Tissue Sarcoma Study, Italian Cooperative Group, and International Society of Pediatric Oncology Malignant Mesenchymal Tumors Committee. Int J Cancer 2010, 128:1232-1239.
65. Neville H.L., Andrassy R.J., Lobe T.E., et al. Preoperative staging, prognostic factors, and outcome for extremity rhabdomyosarcoma: A preliminary report from the Intergroup rhabdomyosarcoma study IV (1991-1997). J Pediatr Surg 2000, 35:317-321.
66. Mandell L., Ghavimi F., LaQuaglia M., et al. Prognostic significance of regional lymph node involvement in childhood extremity rhabdomyosarcoma. Med Pediatr Oncol 1990, 18:466-471.
67. Wiener E.S., Anderson J.R., Ojimba J.I., et al. Controversies in the management of paratesticular rhabdomyosarcoma: Is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma?. Semin Pediatr Surg 2001, 10:146-152.
68. Wiener E.S. Pediatric surgical oncology. Curr Opin Pediatr 1993, 5:110-116.
69. Hayes-Jordan A., Doherty D.K., West S.D., et al. Outcome after surgical resection of recurrent rhabdomyosarcoma. J Pediatr Surg 2006, 41:633-638. discussion 8.
70. Spunt S.L., Smith L.M., Ruymann F.B., et al. Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: A report from the soft tissue sarcoma committee of the children's oncology group. Clin Cancer Res 2004, 10:6072-6079.
71. Mascarenhas L., Lyden E.R., Breitfeld P.P., et al. Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: A report from the children's Oncology Group. J Clin Oncol 2010, 28:4658-4663.
72. Dantonello T.M., Int-Veen C., Harms D., et al. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. J Clin Oncol 2009, 27:1446-1455.
73. Tefft M., Lindberg R.D., Gehan E.A. Radiation therapy combined with systemic chemotherapy of rhabdomyosarcoma in children: Local control in patients enrolled in the Intergroup rhabdomyosarcoma Study. Natl Cancer Inst Monogr 1981, 56:75-81.
74. Wharam M.D., Hanfelt J.J., Tefft M.C., et al. Radiation therapy for rhabdomyosarcoma: Local failure risk for Clinical Group III patients on Intergroup rhabdomyosarcoma study II. Int J Radiat Oncol Biol Phys 1997, 38:797-804.
75. Mandell L., Ghavimi F., Peretz T., et al. Radiocurability of microscopic disease in childhood rhabdomyosarcoma with radiation doses less than 4,000 cGy. J Clin Oncol 1990, 8:1536-1542.
76. Raney R.B., Anderson J.R., Barr F.G., et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: A selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup rhabdomyosarcoma study V. J Pediatr Hematol/Oncol 2001, 23:215-220.
77. Martelli H., Haie-Meder C., Branchereau S., et al. Conservative surgery plus brachytherapy treatment for boys with prostate and/or bladder neck rhabdomyosarcoma: A single team experience. J Pediatr Surg 2009, 44:190-196.
78. Puri D.R., Wexler L.H., Meyers P.A., et al. The challenging role of radiation therapy for very young children with rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 2006, 65:1177-1184.
79. McDonald M.W., Esiashvili N., George B.A., et al. Intensity-modulated radiotherapy with use of cone-down boost for pediatric head-and-neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 2008, 72:884-891.
80. Pappo A.S., Shapiro D.N., Crist W.M., et al. Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol 1995, 13:2123-2139.
81. Karcioglu Z.A., Hadjistilianou D., Rozans M., et al. Orbital rhabdomyosarcoma. Cancer Contr 2004, 11:328-333.
82. Pappo A.S., Meza J.L., Donaldson S.S., et al. Treatment of localized nonorbital, nonparameningeal head and neck rhabdomyosarcoma: Lessons learned from intergroup rhabdomyosarcoma studies III and IV. J Clin Oncol 2003, 21:638-645.
83. Wiener E.S. Head and neck rhabdomyosarcoma. Semin Pediatr Surg 1994, 3:203-206.
84. Walterhouse D.O., Pappo A.S., Baker K.S., et al. Rhabdomyosarcoma of the parotid region occurring in childhood and adolescence. A report from the Intergroup Rhabdomyosarcoma Study Group. Cancer 2001, 92:3135-3146.
85. Hawkins D.S., Anderson J.R., Paidas C.N., et al. Improved outcome for patients with middle ear rhabdomyosarcoma: A children's oncology group study. J Clin Oncol 2001, 19:3073-3079.
86. Raney R.B., Meza J., Anderson J.R., et al. Treatment of children and adolescents with localized parameningeal sarcoma: Experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978-1997. Med Pediatr Oncol 2002, 38:22-32.
87. Defachelles A.S., Rey A., Oberlin O., et al. Treatment of nonmetastatic cranial parameningeal rhabdomyosarcoma in children younger than 3 years old: Results from international society of pediatric oncology studies MMT 89 and 95. J Clin Oncol 2009, 27:1310-1315.
88. Andrassy R.J., Wiener E.S., Raney R.B., et al. Thoracic sarcomas in children. Ann Surg 1998, 227:170-173.
89. Soyer T., Karnak I., Ciftci A.O., et al. The results of surgical treatment of chest wall tumors in childhood. Pediatr Surg Int 2006, 22:135-139.
90. Chui C.H., Billups C.A., Pappo A.S., et al. Predictors of outcome in children and adolescents with rhabdomyosarcoma of the trunk-The St Jude Children's Research Hospital experience. J Pediatr Surg 2005, 40:1691-1695.
91. Raney R.B., Ragab A.H., Ruymann F.B., et al. Soft-tissue sarcoma of the trunk in childhood. Results of the intergroup rhabdomyosarcoma study. Cancer 1982, 49:2612-2616.
92. Young M.M., Kinsella T.J., Miser J.S., et al. Treatment of sarcomas of the chest wall using intensive combined modality therapy. Int J Radiat Oncol Biol Phys 1989, 16:49-57.
93. Akers D.R., Needham M.E. Sarcoma botryoides (rhabdomyosarcoma) of the bile ducts with survival. J Pediatr Surg 1971, 6:474-479.
94. Davis G.L., Kissane J.M., Ishak K.G. Embryonal rhabdomyosarcoma (sarcoma botryoides) of the biliary tree. Report of five cases and a review of the literature. Cancer 1969, 24:333-342.
95. Ito F., Watanabe Y., Harada T., et al. Combined resection of abdominal aorta and inferior vena cava for retroperitoneal rhabdomyosarcoma invading the aortoiliac bifurcation. J Pediatr Surg 1998, 33:1566-1568.
96. Blakely M.L., Lobe T.E., Anderson J.R., et al. Does debulking improve survival rate in advanced-stage retroperitoneal embryonal rhabdomyosarcoma?. J Pediatr Surg 1999, 34:736-741. discussion: 41-2.
97. Raney R.B., Stoner J.A., Walterhouse D.O., et al. Results of treatment of fifty-six patients with localized retroperitoneal and pelvic rhabdomyosarcoma: A report from the Intergroup rhabdomyosarcoma study-IV, 1991-1997. Pediatr Blood Cancer 2004, 42:618-625.
98. Blakely M.L., Andrassy R.J., Raney R.B., et al. Prognostic factors and surgical treatment guidelines for children with rhabdomyosarcoma of the perineum or anus: A report of Intergroup rhabdomyosarcoma studies I through IV, 1972 through 1997. J Pediatr Surg 2003, 38:347-353.
99. La T.H., Wolden S.L., Su Z., et al. Local therapy for rhabdomyosarcoma of the hands and feet: Is amputation necessary?. A Report from the Children's Oncology Group. Int J Radiat Oncol Biol Phys 2011, 80:206-212.
100. Castellino S.M., McLean T.W. Pediatric genitourinary tumors. Curr Opin Oncol 2007, 19:248-253.
101. Ferrer F.A., Isakoff M., Koyle M.A. Bladder/prostate rhabdomyosarcoma: past, present and future. J Urol 2006, 176:1283-1291.
102. Hays D.M., Lawrence W., Crist W.M., et al. Partial cystectomy in the management of rhabdomyosarcoma of the bladder: A report from the Intergroup rhabdomyosarcoma Study. J Pediatr Surg 1990, 25:719-723.
103. Williamson S.R., Lopez-Beltran A., Maclennan G.T., et al. Unique clinicopathologic and molecular characteristics of urinary bladder tumors in children and young adults. Urol Oncol 2010, Epub ahead of print.
104. Arndt C.A., Donaldson S.S., Anderson J.R., et al. What constitutes optimal therapy for patients with rhabdomyosarcoma of the female genital tract?. Cancer 2001, 91:2454-2468.
105. Rodeberg D., Paidas C. Childhood rhabdomyosarcoma. Semin Pediatr Surg 2006, 15:57-62.
106. Raney R.B., Tefft M., Lawrence W., et al. Paratesticular sarcoma in childhood and adolescence. A report from the Intergroup rhabdomyosarcoma studies I and II, 1973-1983. Cancer 1987, 60:2337-2343.
107. Wiener E.S., Lawrence W., Hays D., et al. Retroperitoneal node biopsy in paratesticular rhabdomyosarcoma. J Pediatr Surg 1994, 29:171-177. discussion: 8.
108. Ferrari A., Bisogno G., Casanova M., et al. Is alveolar histotype a prognostic factor in paratesticular rhabdomyosarcoma?. The experience of Italian and German Soft Tissue Sarcoma Cooperative Group. Pediatr Blood Cancer 2004, 42:134-138.
109. Ferrari A., Casanova M., Massimino M., et al. The management of paratesticular rhabdomyosarcoma: A single institutional experience with 44 consecutive children. J Urol 1998, 159:1031-1034.
110. Sandler E., Lyden E., Ruymann F., et al. Efficacy of ifosfamide and doxorubicin given as a phase II "window" in children with newly diagnosed metastatic rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. Med Pediatr Oncol 2001, 37:442-448.
111. McDowell H.P., Foot A.B., Ellershaw C., et al. Outcomes in paediatric metastatic rhabdomyosarcoma: Results of the International Society of Paediatric Oncology (SIOP) study MMT-98. Eur J Cancer 2010, 46:1588-1595.
112. Mattke A.C., Bailey E.J., Schuck A., et al. Does the time-point of relapse influence outcome in pediatric rhabdomyosarcomas?. Pediatr Blood Cancer 2009, 52:772-776.
113. Ferrari A., Miceli R., Meazza C., et al. Soft tissue sarcomas of childhood and adolescence: The prognostic role of tumor size in relation to patient body size. J Clin Oncol 2009, 27:371-376.
114. Smith L.M., Anderson J.R., Qualman S.J., et al. Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy?. A report from the soft tissue sarcoma committee of the children's oncology group. J Clin Oncol 2001, 19:4058-4064.
115. Wharam M.D., Meza J., Anderson J., et al. Failure pattern and factors predictive of local failure in rhabdomyosarcoma: A report of group III patients on the third Intergroup rhabdomyosarcoma Study. J Clin Oncol 2004, 22:1902-1908.
116. Crist W., Gehan E.A., Ragab A.H., et al. The third Intergroup rhabdomyosarcoma Study. J Clin Oncol 1995, 13:610-630.
117. Maurer H.M., Gehan E.A., Beltangady M., et al. The Intergroup rhabdomyosarcoma study-II. Cancer 1993, 71:1904-1922.